DDB 202

Drug Profile

DDB 202

Latest Information Update: 26 Apr 2007

Price : $50

At a glance

  • Originator DyoDelta Biosciences
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 26 Apr 2007 Discontinued - Preclinical for Multiple sclerosis in United Kingdom (unspecified route)
  • 10 Jun 2002 Preclinical trials in Multiple sclerosis in United Kingdom (unspecified route)
  • 10 Jun 2002 DDB 202 is available for licensing [http:www.dyodelta.com]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top